Biomerica Yönetim

Yönetim kriter kontrolleri 3/4

Biomerica CEO'su Zack Irani, Apr1997 tarihinde atandı, in görev süresi 27.58 yıldır. in toplam yıllık tazminatı $ 360.10K olup, şirket hissesi ve opsiyonları dahil olmak üzere 41.7% maaş ve 58.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 6.07% ine doğrudan sahiptir ve bu hisseler $ 330.15K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 7.5 yıldır.

Anahtar bilgiler

Zack Irani

İcra Kurulu Başkanı

US$360.1k

Toplam tazminat

CEO maaş yüzdesi	41.7%
CEO görev süresi	27.6yrs
CEO sahipliği	6.1%
Yönetim ortalama görev süresi	3.1yrs
Yönetim Kurulu ortalama görev süresi	7.5yrs

Son yönetim güncellemeleri

Recent updates

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Jul 14

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Dec 03

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

Dec 02

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Sep 15

Biomerica (BMRA) Investor Presentation - Slideshow

Jun 14

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Jun 13

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Apr 04

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

Mar 08

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Feb 10

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Jan 15

Biomerica soars as its COVID-19 antigen test wins European nod

Jan 12

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

Dec 20

Biomerica clinical trial for IBS nears enrollment completion

Dec 09

How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?

Nov 23

CEO Tazminat Analizi

Zack Irani'un ücretlendirmesi Biomerica'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Aug 31 2024	n/a	n/a	-US$6m
May 31 2024	US$360k	US$150k	-US$6m
Feb 29 2024	n/a	n/a	-US$6m
Nov 30 2023	n/a	n/a	-US$6m
Aug 31 2023	n/a	n/a	-US$6m
May 31 2023	US$141k	US$141k	-US$7m
Feb 28 2023	n/a	n/a	-US$7m
Nov 30 2022	n/a	n/a	-US$6m
Aug 31 2022	n/a	n/a	-US$5m
May 31 2022	US$491k	US$135k	-US$5m
Feb 28 2022	n/a	n/a	-US$4m
Nov 30 2021	n/a	n/a	-US$7m
Aug 31 2021	n/a	n/a	-US$7m
May 31 2021	US$488k	US$137k	-US$7m
Feb 28 2021	n/a	n/a	-US$6m
Nov 30 2020	n/a	n/a	-US$5m
Aug 31 2020	n/a	n/a	-US$4m
May 31 2020	US$330k	US$137k	-US$2m
Feb 29 2020	n/a	n/a	-US$3m
Nov 30 2019	n/a	n/a	-US$2m
Aug 31 2019	n/a	n/a	-US$2m
May 31 2019	US$329k	US$137k	-US$2m
Feb 28 2019	n/a	n/a	-US$2m
Nov 30 2018	n/a	n/a	-US$2m
Aug 31 2018	n/a	n/a	-US$2m
May 31 2018	US$295k	US$137k	-US$1m

Tazminat ve Piyasa: Zack 'nin toplam tazminatı ($USD 360.10K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 650.80K ).

Tazminat ve Kazançlar: Zack şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Zack Irani (58 yo)

27.6yrs

Görev süresi

US$360,103

Tazminat

Mr. Zackary S. Irani, also known as Zack, has been Chief Executive Officer of Biomerica Inc. since April 29, 1997 and is its Director and served as its President. He was Chairman of the Board at Biomerica...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Zackary Irani	CEO & Director	27.6yrs	US$360.10k	6.07% $ 330.2k
Allen Barbieri	Executive Vice-Chairman of the Board & Corporate Secretary	25.1yrs	US$243.98k	0.47% $ 25.3k
Gary Lu	Principal Accounting Officer & CFO	1.7yrs	US$385.64k	0% $ 0
Lucy Liu	Director of Manufacturing & Technical Operations	no data	Veri yok	Veri yok
Robert Carlson	Chief Commercial Officer	2.3yrs	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: BMRA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Zackary Irani	CEO & Director	no data	US$360.10k	6.07% $ 330.2k
Allen Barbieri	Executive Vice-Chairman of the Board & Corporate Secretary	25.1yrs	US$243.98k	0.47% $ 25.3k
Edward Barnholt	Chairman of Strategic Advisory Board	8.3yrs	Veri yok	Veri yok
Harry Leider	Member of Strategic Advisory Board	6.6yrs	Veri yok	Veri yok
Douglas Drossman	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
William Chey	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Jane Emerson	Independent Director	17.6yrs	US$137.71k	0.42% $ 23.0k
Anthony Lembo	Member of Scientific Advisory Board	8.3yrs	Veri yok	Veri yok
David Moatazedi	Independent Director	1.9yrs	US$157.82k	0% $ 0
Catherine Coste	Independent Director	4.2yrs	US$145.21k	0.26% $ 14.2k
Brooks Cash	Chairman of Colorectal Screening Scientific Advisory Board	3yrs	Veri yok	Veri yok
William Whitehead	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok

7.5yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BMRA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.5 yıldır).

Biomerica Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Biomerica, Inc., Annual General Meeting, Dec 13, 2024

Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board

Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors

Biomerica, Inc., Annual General Meeting, Dec 07, 2023

Jack Kenny Joins Biomerica’S Board of Directors

Biomerica Appoints Brian E. Lacy, to the Company’s Scientific Advisory Board

Recent updates

Biomerica Secures Three Key International Patents for inFoods Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis

Nasdaq Grants Biomerica an Additional 180 Calendar Days to Regain Compliance with the Minimum Closing Bid Price Requirement

Biomerica, Inc. Announces Direct-To-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain

First quarter 2025 earnings released: US$0.078 loss per share (vs US$0.067 loss in 1Q 2024)

Biomerica, Inc., Annual General Meeting, Dec 13, 2024

New major risk - Financial position

Full year 2024 earnings released: US$0.35 loss per share (vs US$0.50 loss in FY 2023)

Biomerica, Inc. Launches At-Home Sample Collection for inFoods IBS, Significantly Expanding Access for Millions of IBS Sufferers

Biomerica, Inc. Announces Infoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024

Biomerica, Inc. has filed a Follow-on Equity Offering in the amount of $5.5 million.

Biomerica Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2023)

Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board

Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors

Second quarter 2024 earnings released: US$0.09 loss per share (vs US$0.12 loss in 2Q 2023)

Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?

Biomerica, Inc. Receives US FDA 510(k) Clearance for their Hp Detect Stool Antigen ELISA Test Product Designed to Detect Presence of H. Pylori Bacteria

First quarter 2024 earnings released: US$0.067 loss per share (vs US$0.16 loss in 1Q 2023)

Biomerica, Inc., Annual General Meeting, Dec 07, 2023

Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation

Jack Kenny Joins Biomerica’S Board of Directors

Full year 2023 earnings released: US$0.50 loss per share (vs US$0.36 loss in FY 2022)

Biomerica Inc. Receives Notice of Patent Allowance in China for A Potential Innovative Technology That Includes an Artificial Intelligence Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients

Biomerica Inc. Announces A Significant Advance in the Management of Irritable Bowel Syndrome

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.008 loss in 3Q 2022)

We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.089 loss in 2Q 2022)

Biomerica Appoints Brian E. Lacy, to the Company’s Scientific Advisory Board

Steve Sloan to Step Down as Chief Financial Officer of Biomerica, Inc

Biomerica, Inc. Announces Board Changes

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.12 loss in 1Q 2022)

Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test

Biomerica, Inc., Annual General Meeting, Dec 07, 2022

Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now

Biomerica, Inc. Appoints Robert Carlson as Chief Commercial Officer

Full year 2022 earnings released: US$0.36 loss per share (vs US$0.62 loss in FY 2021)

Biomerica reports FY results

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2023

Price target increased to US$13.00

Biomerica, Inc Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

Biomerica, Inc. Provides Earnings Guidance for the Second Quarter Ended November 30, 2021

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2021)

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Biomerica, Inc. Expects Completion of Patient Enrollment for Its Infoods Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial This Week

Price target increased to US$13.00

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.23 loss in FY 2020)

Biomerica Announces Notice of Allowance for Patent on Product Used to Diagnose and Treat Depression

Biomerica, Inc. Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment

Biomerica (BMRA) Investor Presentation - Slideshow

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.088 loss in 3Q 2020)

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

New 90-day high: US$8.00

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

New 90-day high: US$7.50

Second quarter 2021 earnings released: US$0.13 loss per share

Earnings beat expectations, revenue disappoints

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Biomerica, Inc. Receives CE Mark for its New Covid-19 Rapid Antigen Test for Detection of Covid-19 Infection

Analysts lower revenue estimates to US$8.51m

Biomerica soars as its COVID-19 antigen test wins European nod

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

New 90-day low: US$5.38

Biomerica, Inc. Announces Corporate Secretary Changes